PARIN-E
Enoxaprin Sodium 60mg/0.6 ml mg/ml
What it does
Enoxaparin is a medication that helps prevent and treat blood clots.
Commonly used for: prevention of blood clots after surgery, treatment of deep vein thrombosis (DVT), treatment of pulmonary embolism (PE), prevention of blood clots in patients with certain heart conditions
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.
Sourcing - Kenya onlyRegistration & product details
Source: Zambia Medicines Regulatory Authority · fetched 2026-04-24 14:14:10 · updated 2026-09-24 03:38:59
About this medicine
Enoxaparin is a medication that helps prevent and treat blood clots.
What it treats
- prevention of blood clots after surgery
- treatment of deep vein thrombosis (DVT)
- treatment of pulmonary embolism (PE)
- prevention of blood clots in patients with certain heart conditions
How it works
It works by thinning the blood, making it less likely to form clots.
Who it's for
This medication is for adults who need help preventing or treating blood clots.
Cautions
- • Do not use if you have a history of severe allergic reactions to similar medications.
- • Use with caution if you have bleeding disorders or severe kidney problems.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: enoxaprin
Enoxaparin is a low molecular weight heparin (LMWH) used primarily as an anticoagulant. It is derived from unfractionated heparin and is employed to prevent and treat thromboembolic disorders. Enoxaparin is commonly used in the management of conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and in patients undergoing certain types of surgery to reduce the risk of venous thromboembolism.
Indications
- Prophylaxis of deep vein thrombosis (DVT) in patients undergoing surgery
- Treatment of DVT and pulmonary embolism (PE)
- Prevention of thromboembolic complications in patients with unstable angina or non-ST elevation myocardial infarction (NSTEMI)
- Management of acute ST elevation myocardial infarction (STEMI) in conjunction with percutaneous coronary intervention
- Prevention of thrombus formation in patients with certain medical conditions
Dosage
Children: Refer to the BNF for Children for
Adults: Refer to the BNF for specific dosing guidelines based on the indication and patient factors.
Mechanism of action
Enoxaparin exerts its anticoagulant effect by inhibiting factor Xa and, to a lesser extent, factor IIa (thrombin) in the coagulation cascade. It enhances the activity of antithrombin III, which inhibits the conversion of prothrombin to thrombin and the conversion of fibrinogen to fibrin, thereby preventing clot formation.
Pharmacodynamics
The pharmacodynamic effects of enoxaparin include dose-dependent anticoagulation, which is monitored through anti-factor Xa levels. The drug has a predictable pharmacokinetic profile, allowing for fixed dosing without routine coagulation monitoring in most patients. Enoxaparin's effects are prolonged compared to unfractionated heparin, and it has a lower risk of inducing thrombocytopenia.
Pharmacokinetics
Enoxaparin is administered subcutaneously and is well absorbed, with peak plasma concentrations occurring approximately 3 to 5 hours after administration. It has a bioavailability of approximately 90%, and its elimination half-life is around 4 to 5 hours. The drug is primarily eliminated by renal excretion, necessitating dose adjustments in patients with renal impairment.
Contra-indications
- Active major bleeding
- Severe thrombocytopenia
- Hypersensitivity to enoxaparin or any component of the formulation
- History of heparin-induced thrombocytopenia
- Active ulcer disease
Adverse effects
- Bleeding
- Thrombocytopenia
- Injection site reactions
- Allergic reactions
- Liver enzyme elevation
- Osteoporosis (with long-term use)
- Anemia
Interactions
- Other anticoagulants (may increase bleeding risk)
- Non-steroidal anti-inflammatory drugs (NSAIDs) (may increase risk of gastrointestinal bleeding)
- Antiplatelet agents (e.g., aspirin, clopidogrel) (increased risk of bleeding)
- Certain herbal supplements (e.g., ginkgo biloba, garlic) (may increase bleeding risk)
Precautions
- Use with caution in patients with renal impairment
- Monitor patients with a history of bleeding disorders
- Regular monitoring of platelet counts is recommended
- Use during and after procedures that may increase bleeding risk
Pregnancy
Enoxaparin is classified as category B. It may be used in pregnancy if the benefits outweigh the risks, particularly in patients with a history of thromboembolic events.
Breast-feeding
Enoxaparin is excreted in breast milk in small amounts. Caution is advised, but it is generally considered compatible with breastfeeding.
Storage
Store at room temperature (15-30°C), protect from light. Do not freeze.
Formulations
- Enoxaparin sodium injection (pre-filled syringes)
- Enoxaparin sodium vial for injection
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.
- ADRENALINE INJ 1MG/ML 1ML · Nairobi Pharmaceuticals
- ADVOCATE (FOR CATS) SOLUTION · Bayer
- ATRAPURE 2.5ML INJECTION · Nairobi Enterprises
- ATROMED INJECTION · Dawa
- ATROPINE · Reddys Pharma
- ATROPINE SULPHATE INJ. 0.6MG/ML 1ML · Nairobi Pharmaceuticals